Evidence map›Paper›PMID 36555683›Full record

ArticleInternational journal of molecular sciences2022

Hepatoprotective Activity of Lignin-Derived Polyphenols Dereplicated Using High-Resolution Mass Spectrometry, In Vivo Experiments, and Deep Learning.

Alexey Orlov, Savva Semenov, Gleb Rukhovich, Anastasia Sarycheva, Oxana Kovaleva, Alexander Semenov, Elena Ermakova, Ekaterina Gubareva, Anna E Bugrova, Alexey Kononikhin and 3 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Alexey OrlovSkolkovo Institute of Science and Technology, 30 Bolshoy Boulevard bld. 1, 121205 Moscow, Russia.ORCID 0000-0001-7889-9245
Savva SemenovSkolkovo Institute of Science and Technology, 30 Bolshoy Boulevard bld. 1, 121205 Moscow, Russia.ORCID 0000-0001-9457-3210
Gleb RukhovichSkolkovo Institute of Science and Technology, 30 Bolshoy Boulevard bld. 1, 121205 Moscow, Russia.
Anastasia SarychevaSkolkovo Institute of Science and Technology, 30 Bolshoy Boulevard bld. 1, 121205 Moscow, Russia.
Oxana KovalevaSkolkovo Institute of Science and Technology, 30 Bolshoy Boulevard bld. 1, 121205 Moscow, Russia.
Alexander SemenovN.N. Petrov National Medical Research Center of Oncology, 68 Leningradskaya Str., 197758 Saint Petersburg, Russia.
Elena ErmakovaN.N. Petrov National Medical Research Center of Oncology, 68 Leningradskaya Str., 197758 Saint Petersburg, Russia.ORCID 0000-0003-0259-2567
Ekaterina GubarevaN.N. Petrov National Medical Research Center of Oncology, 68 Leningradskaya Str., 197758 Saint Petersburg, Russia.
Anna E BugrovaEmanuel Institute for Biochemical Physics, Russian Academy of Sciences, 119334 Moscow, Russia.ORCID 0000-0003-1515-9447
Alexey KononikhinSkolkovo Institute of Science and Technology, 30 Bolshoy Boulevard bld. 1, 121205 Moscow, Russia.
Elena I FedorosN.N. Petrov National Medical Research Center of Oncology, 68 Leningradskaya Str., 197758 Saint Petersburg, Russia.
Evgeny NikolaevSkolkovo Institute of Science and Technology, 30 Bolshoy Boulevard bld. 1, 121205 Moscow, Russia.
Alexander ZherebkerSkolkovo Institute of Science and Technology, 30 Bolshoy Boulevard bld. 1, 121205 Moscow, Russia.
Skolkovo Institute of Science and Technology · RUInstitute of Oncology NN Petrov · RUInstitute of Biochemical Physics NM Emanuel · RU

Funding

Russian Science Foundation 22-75-10140
6 · The paper itself

Abstract

Chronic liver diseases affect more than 1 billion people worldwide and represent one of the main public health issues. Nonalcoholic fatty liver disease (NAFLD) accounts for the majority of mortal cases, while there is no currently approved therapeutics for its treatment. One of the prospective approaches to NAFLD therapy is to use a mixture of natural compounds. They showed effectiveness in alleviating NAFLD-related conditions including steatosis, fibrosis, etc. However, understanding the mechanism of action of such mixtures is important for their rational application. In this work, we propose a new dereplication workflow for deciphering the mechanism of action of the lignin-derived natural compound mixture. The workflow combines the analysis of molecular components with high-resolution mass spectrometry, selective chemical tagging and deuterium labeling, liver tissue penetration examination, assessment of biological activity in vitro, and computational chemistry tools used to generate putative structural candidates. Molecular docking was used to propose the potential mechanism of action of these structures, which was assessed by a proteomic experiment.

Indexed as

Deep LearningNon-alcoholic Fatty Liver DiseaseHumansLigninMass SpectrometryMolecular Docking SimulationPolyphenolsProteomicsLigninPolyphenolscomplex mixturesdereplicationhepatoprotective activitylabelingmass spectrometryNAFLDpolyphenolic compositionstructure

Identifiers

PMID36555683
PMCPMC9781348
OpenAlexW4312194740

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.